Latest News and Press Releases
Want to stay updated on the latest news?
-
Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði gefið út nýja hluti í skiptum fyrir breytileg skuldabréf, sem upprunalega voru gefin út af Alvotech í nóvember og desember 2022 og voru með...
-
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
-
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key...
-
Alvotech (NASDAQ: ALVO) kynnti í dag eftirfarandi óendurskoðaða áætlun um rekstrarniðurstöðu annars ársfjórðungs og á fyrri helmingi ársins 2024. Reiknað er með mettekjum Alvotech frá upphafi á...
-
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
-
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that holders of the majority of...
-
Alvotech (NASDAQ: ALVO) tilkynnti í dag að eigendur meirihluta breytilegra skuldabréfa félagins sem upphaflega voru útgefin 16. nóvember og 20. desember 2022 með lokagjalddaga 20. desember 2025, hafi...
-
REYKJAVIK, Iceland , June 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
-
Advanz Pharma secures rights to commercialize Alvotech’s biosimilar candidate for Eylea® in Europe Advanz Pharma will leverage its existing specialty and hospital capabilities in Europe to ensure...
-
Advanz Pharma secures rights to commercialize Alvotech’s biosimilar candidate for Eylea® in EuropeAdvanz Pharma will leverage its existing specialty and hospital capabilities in Europe to ensure...